RxDoctor Payments Data

Kaytie Fratzke, PA

Physician Assistant · Tulsa, OKNPI 1497124515

Payments from drug & device makers

$3,607in general payments, 2019–2025

Across 174 payments — averaging $20.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$901
  • Indivior Inc.$565
  • Otsuka America Pharmaceutical, Inc.$391
  • Vanda Pharmaceuticals Inc.$349
  • Alkermes, Inc.$331
  • Neurocrine Biosciences, Inc.$302
  • plus $769 from 7 others

What the payments were for

  • Food & beverage$3,50797%
  • Education$1003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,607 in reported general payments places this provider in the 85th percentile of 1,491 physician assistant providers in Oklahoma.

See all physician assistant providers in Oklahoma

Medicare billing

Part B allowed, 2024
$6,249
Medicare patients
43
Services billed
91

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole17$44,333
Invega SustennaPaliperidone Palmitate16$36,636
Duloxetine Hcl73$2,105
Hydroxyzine Hcl40$985
Buspirone Hcl37$736
Mirtazapine49$588
Aripiprazole37$548
Bupropion XlBupropion Hcl36$500
Trazodone Hcl95$494
Escitalopram Oxalate64$388
Quetiapine Fumarate22$367
Olanzapine OdtOlanzapine13$289
Prazosin Hcl16$250
Hydroxyzine Pamoate19$224
Lamotrigine38$221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$391$44,33317 claims
Johnson & JohnsonInvega Sustenna$901$36,63616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,491 physician assistant providers in Oklahoma.

Other physician assistant in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →